10 Mar
2020
16:30 E.S.T.

US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis

Read more

04 Mar
2020
16:30 E.S.T.

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results

Read more

04 Mar
2020
16:05 E.S.T.

Cellectis and Servier Execute the Amendment Confirming the Expansion of their Collaboration on UCART19 Products

Read more

25 Feb
2020
16:30 E.S.T.

Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST

Read more

18 Feb
2020
16:30 E.S.T.

Cellectis and Servier Expand Collaboration on UCART19 Products

Read more

15 Jan
2020
16:30 E.S.T.

First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia

Read more

12 Jan
2020
16:00 E.S.T.

Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement

Read more

06 Jan
2020
16:30 E.S.T.

An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery

Read more

02 Dec
2019
16:30 E.S.T.

1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Read more

20 Nov
2019
16:30 E.S.T.

Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells

Read more